A statement released earlier today by RBC Capital Markets about Sarepta Therapeutics (NASDAQ:SRPT) bumps the target price to $83.00
- Updated: September 19, 2016
Sarepta Therapeutics (NASDAQ:SRPT) had its price target bumped up to $83 by RBC Capital Markets in a report issued Monday September 19 2016. The increased target price suggests a potential upside of 0.70% from the company’s most recent stock close price.
On 7/22/2016, Needham released a statement for Sarepta Therapeutics(NASDAQ:SRPT) raised the target price from $20.00 to $26.00 that suggested an upside of 0.15%.
Boasting a price of $48.94, Sarepta Therapeutics (NASDAQ:SRPT) traded 91.30% higher on the day. The last stock close is up 163.13% from the two hundred day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. SRPT has registered a 50-day average of $26.16 and 200-day average of $20.47. Trading volume was was up over the average, with 29,541,278 shares of SRPT changing hands over the typical 2,328,380 shares.
Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $56.18. Sarepta Therapeutics’s market cap is presently $0.0.
A total of 13 analysts have issued a report on the company. Three firms rate the stock a strong buy, one analyst rate the stock a buy, five analyts rate the stock a hold, four firms rate the stock to underperform, and finally one brokeragerate the stock as sell with an average target stock price of $20.77
About Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.